Safety and Tolerability of Recombinant Humanized Anti-PD-1 Monoclonal Antibody for Patients With Advanced Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: BIOLOGICAL: humanized anti-PD-1 monoclonal antibody toripalimab
Sponsor: Shanghai Junshi Bioscience Co., Ltd.